Fragment-based lead discovery: leads by design (Q28262032)

Identification of "latent hits" in compound screening collections

Europe PubMed Central

title

Fragment-based lead discovery: leads by design (English)

0 references

1 reference

Robin A E Carr

1

0 references

Miles Congreve

series ordinal

2

0 references

Christopher W Murray

series ordinal

3

0 references

David C Rees

series ordinal

4

0 references

language of work or name

English

0 references

publication date

15 July 2005

0 references

published in

Drug Discovery Today

0 references

volume

10

0 references

issue

14

0 references

page(s)

987-92

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

High-throughput drug discovery: what can we expect from HTS?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

Molecular complexity and its impact on the probability of finding leads for drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

Is there a difference between leads and drugs? A historical perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

Fragment-Based Drug Discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

Fragment-based lead discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

Navigating chemical space for biology and medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

Identification and Prediction of Promiscuous Aggregating Inhibitors among Known Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

Ligand efficiency: a useful metric for lead selection

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

The maximal affinity of ligands

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

A ‘Rule of Three’ for fragment-based lead discovery?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

The SHAPES strategy: an NMR-based approach for lead generation in drug discovery.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

Fragment-based lead discovery using X-ray crystallography.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

PRO_SELECT: combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective factor Xa inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

Discovering high-affinity ligands for proteins: SAR by NMR

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

In situ assembly of enzyme inhibitors using extended tethering

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

Ketones as building blocks for dynamic combinatorial libraries: highly active neuraminidase inhibitors generated via selection pressure of the biological target

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

Target-induced formation of neuraminidase inhibitors from in vitro virtual combinatorial libraries

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

Detection of ligands from a dynamic combinatorial library by X-ray crystallography.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

A comparison of physiochemical property profiles of development and marketed oral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

Selective optimization of side activities: another way for drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

Druggability indices for protein targets derived from NMR-based screening data

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

Combinatorial target-guided ligand assembly: identification of potent subtype-selective c-Src inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

Custom chemical microarray production and affinity fingerprinting for the S1 pocket of factor VIIa

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

SAR by MS: a ligand based technique for drug lead discovery against structured RNA targets

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

Structure-activity relationships by mass spectrometry: identification of novel MMP-3 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

Tethering: fragment-based drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

NMR-Based screening with competition water-ligand observed via gradient spectroscopy experiments: detection of high-affinity ligands

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

Spin label enhanced NMR screening

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

Automation of NMR measurements and data evaluation for systematically screening interactions of small molecules with target proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

Discovering novel ligands for macromolecules using X-ray crystallographic screening

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903511-7

7 January 2021

10.1016/S1359-6446(05)03511-7

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1657299

1657299

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference